Willem Mulder, PhD

SLAS Europe 2026 Keynote Speaker

Willem Mulder, PhD, is a biomedical engineer, inventor and entrepreneur. He develops innovative, bioengineered nanomedicines and controlled-release systems for immunotherapy in cancer, inflammatory, and cardiovascular diseases, as well as to prevent allograft rejection in organ transplantation.

After acquiring a PhD in biomedical engineering from the Eindhoven University of Technology (TU/e) in 2006, Mulder was recruited by the Icahn School of Medicine at Mount Sinai in New York. He founded Mount Sinai’s Nanomedicine Lab and was appointed as a tenured Professor of Radiology and Professor of Oncological Sciences. Mulder has published over 200 papers in top scientific journals, including Cell, Nature Nanotechnology, Nature Biomedical Engineering, Immunity, and Science Translational Medicine.

Mulder was the principal investigator of multiple National Institutes of Health grants, including three R01s and a P01 Project from the Heart, Lung, and Blood Institute, a P01 Project from the National Institute of Allergies and Infectious Diseases, as well as two R01s from the National Cancer Institute, and several co-investigator subawards. Besides his work at Mount Sinai, he held part-time professorships at the Amsterdam UMC (2012 – 2018) and at TU/e (2018 – present). In 2013, he received a Vidi grant, and in 2018, he was awarded a Vici grant, both from the Dutch Science Foundation (NWO).

In 2021, Mulder was awarded an ERC Advanced Grant and returned to the Netherlands, where he established the MulderLab, a research group spanning the Radboud University Medical Center and TU/e.

Besides his academic activities, he co-founded Trained Therapeutix Discovery in 2019. This biotech startup aims to treat detrimental immune-mediated diseases. He currently serves as the company’s Chief Scientific Officer. In the Netherlands, he initiated and co-founded the biotech incubator BioTrip and the contract research organization Nanoworx.